ARTICLE | Product Development
Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint
February 8, 2020 1:47 AM UTC
Myriad misses Street as CEO Capone departs
Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting fiscal 2Q20 EPS and revenues that missed consensus estimates and announcing the departure of President and CEO Mark Capone. R. Bryan Riggsbee will serve as interim president and CEO while remaining CFO. The company attributed the revenue shortfall to its prenatal business...